Ultrasound Cyclo Plasty in Glaucoma: 2-Year Outcomes

J Glaucoma. 2022 Oct 1;31(10):834-838. doi: 10.1097/IJG.0000000000002078. Epub 2022 Jul 18.

Abstract

Prcis: UCP offers reasonable IOP control and reduction of the antiglaucoma medication burden.

Purpose: The purpose of this study is to evaluate the 2-year outcomes of Ultrasound Cyclo Plasty (UCP) in uncontrolled glaucoma.

Materials and methods: A retrospective cohort study included patients with uncontrolled primary or secondary glaucoma who underwent UCP at King Abdul Aziz University Hospital, Riyadh, Saudi Arabia, between 2016 and 2021. The main outcome measures were intraocular pressure (IOP), number of antiglaucoma medications, and presence of vision-threatening complications. The surgical outcome of each eye was classified as complete success, qualified success, or failure based on the main outcome measures.

Results: One hundred and eighty-two eyes of 158 patients were included in the study. The mean follow-up period was 29.71 months (±18.1). The IOP and the number of antiglaucoma medications decreased significantly from a mean of 23.46 mm Hg (±6.3) and 3.33 (±0.9) to 17.33 (±7.1) and 2.14 (±1.4), and 16.24 (±6.3) and 1.90 (±1.5) on the 12th and 24 months, respectively. The overall success rates were 78.0% (143/182) and 85.6% (95/111), and the failure rates were 21.4% (39/182) and 14.4% (16/111) on the 12th and 24th months, respectively. The most common complications were cataract development/progression and anterior chamber reaction.

Conclusions: UCP offers reasonable IOP control and reduction of the antiglaucoma medication burden.

MeSH terms

  • Antiglaucoma Agents
  • Follow-Up Studies
  • Glaucoma* / diagnosis
  • Glaucoma* / surgery
  • Humans
  • Intraocular Pressure*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antiglaucoma Agents